BRAF and Miyoshi myopathy: In order to outline practical orientation points, we retrospectively reviewed the medical records of MM patients from our institution treated with BRAF/MEK inhibitors and PD1 blockades in order to define the incidence of oligoprogression defined as a condition characterized by a progression of a solitary or few (≤3) metastases in a single site or organ suitable of local treatment, while all the rest of the disease had already responded or was stable to the ongoing systemic therapy.